期刊文献+

miR-34a和miR-15b在NSCLC患者血清表达及与病理特征的关系

下载PDF
导出
摘要 目的探讨微小RNA-34a(miR-34a)和微小RNA-15b(miR-15b)在非小细胞肺癌(non-small-cell lung carcinoma,NSCLC)患者血清中的表达及与病理特征的关系。方法选取93例NSCLC患者为观察组,30例体检健康的志愿者为对照组。采用实时荧光定量PCR(real-time fluorescence quantitative PCR,RTFQ PCR)检测血清miR-34a和miR-15b表达,分析其与病理特征的关系。结果与对照组比较,观察组血清miR-34a表达增加,而miR-15b表达降低,差异均有统计学意义(P<0.05)。TNM分期Ⅳ期、有淋巴结转移、有吸烟史的患者miR-34a表达[(1.73±0.92)、(1.69±0.86)、(1.64±0.84)]比TNM分期Ⅲb期、无淋巴结转移、无吸烟史患者[(1.09±0.61)、(1.12±0.68)、(1.20±0.63)]高,TNM分期Ⅳ期、有淋巴结转移的患者miR-15b表达[(0.14±0.04)、(0.12±0.05)]比TNM分期Ⅲb期、无淋巴结转移患者[(0.33±0.15)、(0.37±0.18)]低,差异均有统计学意义(P<0.05)。结论 NSCLC患者血清miR-34a表达增加,而miR-15b表达降低,且与病理特征有关。
作者 路琳君
出处 《河南医学高等专科学校学报》 2018年第4期382-384,共3页 Journal of Henan Medical College
  • 相关文献

参考文献5

二级参考文献93

  • 1项永兵,高玉堂.非吸烟女性肺癌危险因素的多分类logistic模型分析[J].中国卫生统计,2005,22(2):66-70. 被引量:30
  • 2邹小农.中国肺癌流行病学[J].中华肿瘤防治杂志,2007,14(12):881-883. 被引量:152
  • 3王梅,魏文强.中国肺癌患者住院人次增长现况及其主要影响因素分析[J].中国肿瘤,2007,16(9):672-675. 被引量:25
  • 4Rapp E, Pater JL, Will an A, et al. Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer-report of a Cana-dian multicenter randomized trial[J]. Clin Oncol, 1988,6(4):633-641.
  • 5Marino P, Pampallona S, Preatoni A, et al. Chemo--therapy us supportive care in advanced non-small-cell lung cancer- Rsults of a metaanalysis of the literature[J].Chest,1994,106(3) :861-865.
  • 6Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: A Meta-analysis using updated data on individual patients from 52 randomised clinical trials [J]. BMJ,1995,311(7010):899-909.
  • 7Grilli R,Oxman AD,Julian JA. Chemotherapy for advanced nonsmall-cell lung cancer: How much benefit is enough? [J]. Clin On col, 1993,11 (10) : 1866-1872.
  • 8Goldie JH, Coldman AJ. A mathematical model for relating the drug sensitivity of tumors to their spontaneous mutation rate [J]. Cancer Treat Rep,1979,6301-12) :1727-1733.
  • 9Day RS. Treatment sequencing, asymmetry, and uncertainty: protocol strategies for combination chemotherapy [J]. Cancer Res, 1986,46(8):3876-3885.
  • 10Socinski MA, Schell MJ , Peterman A, et al. Phase ill trial comparing a defined duration of therapy us continuous therapy followed by second-line therapy in advanced-stage ill B/ N non-small-cell lung cancer[J]. Clin Oncol,2002 ,20(5): 1335-1343.

共引文献667

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部